research Acquired ichthyosis, alopecia and loss of hair pigment associated with leiomyosarcoma
Removing a tumor may resolve associated skin and hair symptoms.
Search
for
Sort by
Research
960-990 / 1000+ resultsresearch Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
research Fully Natural Lecithin Encapsulated Nano-Resveratrol for Anti-Cancer Therapy
Lecithin-encapsulated resveratrol nanoparticles could be a safe and effective anti-cancer treatment.
research A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor
New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
research Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in MCF7, T47D and BT483 breast cancer cell lines
Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.
research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
research Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
research Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation
Overexpression of HDGF in melanocytes does not cause cancer.
research Reporting on Adverse Clinical Events
The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
research Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages
Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
research Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
research The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis
BMS-470539 reduces skin fibrosis and inflammation.
research Pharmacological Mobilization of Endogenous Bone Marrow Stem Cells Promotes Liver Regeneration after Extensive Liver Resection in Rats
Using a drug to activate bone marrow stem cells can help the liver regenerate and function better after major surgery in rats.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research The Efficacy of Baricitinib as a Treatment Option for Alopecia, In Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
research Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
research Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia
Suppressing eIF4E can prevent hair loss from chemotherapy.
research A review of Janus kinase inhibitor use in scarring alopecia
Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
research SRD5A2 and emerging therapies in androgen-driven disorders
research Pathology in Practice
The cat had liver cancer and a related hair loss condition, with a likely cause being bile duct cancer.
research Selective androgen receptor modulators: a critical appraisal
SARMs show promise but need more evidence to prove they're better than traditional androgens.
research Onychomatricoma with classic features: Case report and review of the literature
Hair loss is a common side effect of hormone treatments for cancer.
research Two Birds that Exclude Each Other: The Renbök Phenomenon
Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
research Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide
Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
research Drug safety evaluation of exemestane
Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.